These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of childhood renal cell carcinoma with lymph node metastasis: two cases and a review of literature. Uchiyama M; Iwafuchi M; Yagi M; Iinuma Y; Ohtaki M; Tomita Y; Hirota M; Kataoka S; Asami K J Surg Oncol; 2000 Dec; 75(4):266-9. PubMed ID: 11135269 [TBL] [Abstract][Full Text] [Related]
4. Hyperplasia of axillary nodes in patients undergoing immunotherapy. Loyer E; David C; Sella A; Ellerhorst J AJR Am J Roentgenol; 1997 Nov; 169(5):1359-62. PubMed ID: 9353459 [TBL] [Abstract][Full Text] [Related]
5. Complete remission of extensive metastatic renal cancer following immunotherapy. Plowman PN; Costello J; O'Donoghue N Clin Oncol (R Coll Radiol); 1997; 9(3):176-80. PubMed ID: 9269551 [TBL] [Abstract][Full Text] [Related]
6. A case of posttherapeutic sclerotic change of bone metastasis from renal cell carcinoma which proved histopathologically to be complete response. Shimizu TS; Uchida T; Shibata Y; Satoh J; Sugihara S; Maehara Y Urol Int; 1994; 53(3):172-5. PubMed ID: 7645148 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment of renal cell carcinoma with mediastinal lymph node metastasis by interleukin-2: a case report. Tokunaga M; Masuda A; Mukai M; Nakamura H; Iwaki K; Terachi T Tokai J Exp Clin Med; 2005 Jul; 30(2):111-5. PubMed ID: 16146201 [TBL] [Abstract][Full Text] [Related]
10. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma. Little B; Young M; Ho KJ Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831 [TBL] [Abstract][Full Text] [Related]
11. Present achievements in the medical treatment of metastatic renal cell carcinoma. Ravaud A; Debled M Crit Rev Oncol Hematol; 1999 Jun; 31(1):77-87. PubMed ID: 10532192 [No Abstract] [Full Text] [Related]
12. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623 [TBL] [Abstract][Full Text] [Related]
13. Partial nephrectomy used to treat renal cell carcinoma arising in a live donor transplant kidney. Lamb GW; Baxter GM; Rodger RS; Aitchison M Urol Res; 2004 May; 32(2):89-92. PubMed ID: 15250100 [TBL] [Abstract][Full Text] [Related]
14. [A case of metastatic spinal tumor from renal cancer reduced by interferon-alpha]. Suzuki T; Tokuno H; Hayashi H; Egashira M; Kiyama M; Kubota K; Hirayama A; Hakuba A No Shinkei Geka; 1993 Nov; 21(11):1049-53. PubMed ID: 8255382 [TBL] [Abstract][Full Text] [Related]
15. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. Pantuck AJ; Belldegrun AS; Figlin RA N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660 [No Abstract] [Full Text] [Related]
16. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC). Brinkmann OA; Bruns F; Prott FJ; Hertle L Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150 [TBL] [Abstract][Full Text] [Related]
17. Metastatic renal cell carcinoma of the spine: surgical treatment and results. Jackson RJ; Loh SC; Gokaslan ZL J Neurosurg; 2001 Jan; 94(1 Suppl):18-24. PubMed ID: 11147860 [TBL] [Abstract][Full Text] [Related]
18. [Combined immunotherapy using interferon-alpha, interleukin-2 and lymphokine-activated killer cells--improvement of quality of life in patients with advanced renal cell carcinoma]. Watanabe J; Hattori T; Satoh M; Akimoto M Nihon Hinyokika Gakkai Zasshi; 1995 Jun; 86(6):1156-63. PubMed ID: 7609359 [TBL] [Abstract][Full Text] [Related]
19. [A case of multiple lung metastases and cervical lymph node metastasis of renal cell carcinoma failing to respond to interferon-alpha (IFN-alpha) but markedly responding to interleukin-2 (IL-2)]. Nishikimi T; Ishida R; Yamada H; Yokoi K; Kobayashi H; Obata K Nihon Hinyokika Gakkai Zasshi; 2004 Jan; 95(1):54-8. PubMed ID: 14978942 [TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy in the management of metastatic renal carcinoma]. Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]